ANGPT1 and pulmonary hypertension: Gonzalez et al. (2018), described Ang-(1–9) as having a protective role in hypertensive end-organ damage, by demonstrating reduction of collagen deposition and myofibroblast in heart, kidney and aorta when infused in DOCA-salt hypertensive rats (Gonzalez et al., 2018). Additionally, in rats with pulmonary hypertension the antifibrotic effects of Ang-(1–9) were replicated. Treatment with Ang-(1–9) in an monocrotaline induced pulmonary hypertensive model reduced pulmonary damage via the AT2R (Cha et al., 2018) (Figure 3).